ArticleJournal of clinical medicine2020
A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in Healthy Ageing and Age-Related Macular Degeneration.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Repeated low-level red-light therapy for improving asthenopic symptoms and accommodation in presbyopia.Annals of medicine · 2026Trial
- Near-Infrared and Red-Light Photobiomodulation for Ocular Aging and Diseases: A Narrative Review.Ophthalmology and therapy · 2026Review
- Functional and Structural Outcomes of Photobiomodulation Therapy in Dry Age-Related Macular Degeneration: A Single-Center Experience.Journal of clinical medicine · 2026Article
- Review
- Mesopic and Low-Contrast Visual Acuity Deficits in Retinitis Pigmentosa: Clinical Markers for Early Functional Impairment.Journal of clinical medicine · 2025Article
- Photobiomodulation in ocular therapy: current status and future perspectives.International journal of ophthalmology · 2025Review
- Near infrared/ red light therapy a potential countermeasure for mitochondrial dysfunction in spaceflight associated neuro-ocular syndrome (SANS).Eye (London, England) · 2024Article
- Photobiomodulation therapy for congenital color vision deficiency: results of a preliminary randomized clinical trial.Frontiers in medicine · 2024Article
- Photobiomodulation use in ophthalmology - an overview of translational research from bench to bedside.Frontiers in ophthalmology · 2024Review
- Evaluation of Photobiomodulation and Boldine as Alternative Treatment Options in Two Diabetic Retinopathy Models.International journal of molecular sciences · 2023Article
- Mitochondrial decline in the ageing old world primate retina: Little evidence for difference between the centre and periphery.PloS one · 2023Article
- Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases.Biomolecules · 2022Review
- Effects of Photobiomodulation in Patients Presenting with Reticular Pseudodrusen: A Retrospective Observational Case Series Study.Medicina (Kaunas, Lithuania) · 2022Observational
- Antiangiogenic activity of photobiomodulation in experimental model using chorioallantoic embryonic membrane of chicken eggs.Arquivos brasileiros de oftalmologia · 2022Article
- Weeklong improved colour contrasts sensitivity after single 670 nm exposures associated with enhanced mitochondrial function.Scientific reports · 2021Article
- Red Light Irradiation In Vivo Upregulates DJ-1 in the Retinal Ganglion Cell Layer and Protects against Axotomy-Related Dendritic Pruning.International journal of molecular sciences · 2021Article
- Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Limited evidence suggests that the application of 670 nm of red light alters the course of aged decline. A previous report on 18 patients showed regression of drusen and improvement in visual functions in patients with intermediate age-related macular degeneration (AMD) by 12 months. We evaluated the functional and structural effects of applying 670 nm light to 31 patients with intermediate AMD and 11 people aged 55 years or above with normal retina. The study eyes were treated daily in the morning with a 670 nm hand-held light source housed in a torch-like tube that emitted energy equivalent to 40 mW/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.